Jocasta Neuroscience, Inc.

About Jocasta Neuroscience, Inc.

Jocasta Neurosciences is focused on improving cognitive health and aging through the therapeutic potential of the Klotho protein. The company aims to replenish Klotho levels to enhance brain function, reduce toxicity, and lower the risk of neurodegenerative diseases like Alzheimer's.

Products & Services

Klotho JN-0413:A proprietary synthetic subcutaneous formulation, positioned as a first-in-class and best-in-class treatment for improving cognitive health and aging, with human trials estimated to begin in 2026 pending manufacturing.

Specialties

Cognitive Health Neurodegenerative Diseases Klotho Protein Therapeutics Brain Aging Alzheimer's and Parkinson's Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 35000000 MR: - FA: $35 million FAN: 35000000	D: 2025-08-12 FD: 2025-08-12	5 investors

Series A Latest

2025-08-12

$35.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nathaniel (Ned) David

PhD

LinkedIn (Pro only)

M

Michael H. Davidson

Professor of Medicine and Founding Chief Executive Officer of New Amsterdam Pharma

LinkedIn (Pro only)

Y

Yan Poon

Scientist, Entrepreneur, and Visionary Leader

LinkedIn (Pro only)

P

Peter Attia

Director of the Alzheimer's Disease Research Center at Columbia University

A

Albert Agro

CEO

J

Jordan Dubow

CMO

View 13 more team members with Pro

Unlock Full Team Directory

Recent News